Patents by Inventor Anne Eveno-Nobile

Anne Eveno-Nobile has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for detecting aggregate-forming circulating protein forms using an agent for aggregating said forms and an agent for capturing formed aggregates
    Patent number: 8158441
    Abstract: The present invention concerns a method for detecting aggregate-forming circulating protein forms in a biological sample of human origin that may contain said aggregate-forming circulating protein forms, characterized in that it uses a non-protein agent I producing aggregation of the circulating forms of the noninfectious proteins involved in pathological aggregation processes of the central nervous system and/or a non-protein agent II for capturing the natural aggregrates of aggregate-forming circulating protein forms or the aggregates induced by said agents I.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: April 17, 2012
    Assignees: Biomerieux S.A., Centre National de la Recherche Scientifique, Universite Claude Bernard Lyon 1
    Inventors: Sébastien Cecillon, Anthony William Coleman, Anne Eveno-Nobile, Hervé Perron, Marc Rodrigue
  • Method of isolating cytotoxic heterocomplex associated with multiple sclerosis
    Patent number: 7700294
    Abstract: The invention relates to an isolated cytotoxic factor which is associated with multiple sclerosis and which is selected from the heterocomplex GM2AP/GM2/MRP14 and mutated GM2AP/GM2/MRP14, and to the method of detecting said factor in a biological sample to be tested. The inventive method comprises the following steps consisting in: (i) bringing the biological sample into contact with at least one capture antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and with at least one labeled detection antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and (ii) detecting and/or quantifying the cytotoxic factor by detecting and/or quantifying the labeled detection antibody.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: April 20, 2010
    Assignees: Biomerieux, Institut National de la Sante et de la Recherche Medicale
    Inventors: Hervé Perron, Anne Eveno-Nobile, Jacques Portoukalian, Nicole Battail-Poirot
  • Method for Detecting Aggregate-Forming Circulating Protein Forms Using an Agent for Aggregating Said Forms and an Agent for Capturing Formed Aggregates
    Publication number: 20100062540
    Abstract: The present invention concerns a method for detecting aggregate-forming circulating protein forms in a biological sample of human origin that may contain said aggregate-forming circulating protein forms, characterized in that it uses a non-protein agent I producing aggregation of the circulating forms of the noninfectious proteins involved in pathological aggregation processes of the central nervous system and/or a non-protein agent II for capturing the natural aggregrates of aggregate-forming circulating protein forms or the aggregates induced by said agents I.
    Type: Application
    Filed: July 7, 2006
    Publication date: March 11, 2010
    Applicants: BIOMERIEUX S.A., CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventors: Sébastien Cecillon, Anthony William Coleman, Anne Eveno-Nobile, Hervé Perron, Marc Rodrigue
  • Isolated cytotoxic factor associated with multiple sclerosis and method of detecting said cytotoxic factor
    Publication number: 20070065881
    Abstract: The invention relates to an isolated cytotoxic factor which is associated with multiple sclerosis and which is selected from the heterocomplex GM2AP/GM2/MRP14 and mutated GM2AP/GM2/MRP14, and to the method of detecting said factor in a biological sample to be tested. The inventive method comprises the following steps consisting in: (i) bringing the biological sample into contact with at least one capture antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and with at least one labeled detection antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and (ii) detecting and/or quantifying the cytotoxic factor by detecting and/or quantifying the labeled detection antibody.
    Type: Application
    Filed: December 22, 2004
    Publication date: March 22, 2007
    Applicant: Institut National de la Sante et de la Recherche Medicale(I.N.S.E.R.M.)
    Inventors: Herve Perron, Anne Eveno-Nobile, Jacques Portoukalian, Nicole Battail-Poirot